Does Sapropterin Work for PKU Symptoms?
Sapropterin dihydrochloride (Kuvan) reduces blood phenylalanine (Phe) levels in phenylketonuria (PKU) patients responsive to it, alleviating symptoms like cognitive impairment, behavioral issues, and developmental delays tied to high Phe.[1] In clinical trials, 20-50% of patients classified as BH4-responsive saw Phe drop by at least 30% within 4 weeks, with sustained effects allowing dietary Phe restriction to ease.[2] Real-world data shows average Phe reductions of 25-35% in responders, improving neuropsychiatric symptoms over 1-6 years.[3]
How Do You Know If You're Responsive?
Testing involves a 24-48 hour Phe challenge under controlled diet; responders maintain Phe below 360 μmol/L.[1] Genetic markers like PAH variants predict response in ~20% of classic PKU cases, but trial confirms it—non-responders see no benefit.[4] Kids under 4 respond best; adults less so.[2]
What Symptoms Does It Target?
It primarily lowers hyperphenylalaninemia, indirectly easing intellectual disability, ADHD-like behaviors, anxiety, and eczema in PKU.[3] No direct fix for non-Phe symptoms like seizures from untreated cases.[1] Long-term use (up to 10 years) stabilizes cognition in responders.[5]
Common Side Effects and Risks
Headache (13%), runny nose (12%), and sore throat occur; serious risks include hypersensitivity (pharyngeal swelling) in 1-2%.[1] Phe can rebound if stopped abruptly, worsening symptoms.[2] Not for all PKU types—ineffective in ~80%.[4] Monitor Phe monthly.[1]
How Does It Compare to Diet Alone?
Diet restricts Phe intake but is hard to maintain; sapropterin lets patients eat 40-60% more protein while controlling Phe.[3] Combo therapy outperforms diet alone in responders, with better quality of life scores.[5] Costlier—$50K-$100K/year vs. formula diets at $10K/year.[6]
Who Makes It and When Do Patents Expire?
BioMarin holds patents; core composition patent expired 2020 in US, but method-of-use and pediatric exclusivity run to 2024-2029.[7] Generics unlikely before 2029 due to litigation.[7] DrugPatentWatch.com
[1] Kuvan Prescribing Information, BioMarin 2023.
[2] Levy et al., Lancet 2007;370:337.
[3] Vockley et al., Mol Genet Metab 2012;106:12.
[4] Blau et al., J Inherit Metab Dis 2010;33:5.
[5] Long-term registry, Mol Genet Metab 2019;127:230.
[6] Orphanet Journal 2021;16:312.
[7] DrugPatentWatch.com, accessed 2024.